GSK Adult RSV Vaccine: 3 Things Primary Care Clinicians Should Remember

Medical director of the NFID William Schaffner, MD, shares 3 things about the RSV vaccine that should be top of mind for primary care clinicians.

In a recent conversation, Patient Care Online asked infectious disease specialist William Schaffner, MD, 3 things he would want to tell primary care clinicians about Arexvy™ (GSK), the first respiratory syncytial virus (RSV) vaccine aproved by the US Food and Drug Administration (FDA). The novel vaccine was approved May 3, 2023, for the prevention of lower respiratory tract disease caused by RSV in adults aged ≥60 years.

"First of all, the new vaccine is very safe. But even more importantly, I would urge them to learn more about RSV in older persons," said Schaffner, a well-known infectious disease expert from Vanderbilt University School of Medicine and medical director of the National Foundation for Infectious Diseases.

The full interview follows here.

William Schaffner, MD, is medical director of the National Foundation for Infectious Diseases, professor of preventive medicine in the Department of Health Policy, and professor of medicine in the Division of Infectious Diseases at Vanderbilt University School of Medicine in Nashville, TN.

Twitter: @NFIDvaccines